Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ajog.2023.07.011 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Corrigendum to 'Levonorgestrel 52 mg intrauterine system efficacy and safety through 8 years of use' [American Journal of Obstetrics and Gynecology 2022;227:871.e1-871.e7].
Am J Obstet Gynecol
September 2023
Medicines 360, San Francisco, CA.
Corrigendum to "Double-blind, randomized, placebo-controlled study on the effect of misoprostol on ease of consecutive insertion of the levonorgestrel-releasing intrauterine system".
Contraception
March 2023
Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden. Electronic address:
Corrigendum to "Complete pathological response following levonorgestrel intrauterine device in clinically stage 1 endometrial adenocarcinoma: Results of a randomized clinical trial" [Gynecologic Oncology 161 (2021) 143-151].
Gynecol Oncol
August 2021
Queensland Centre for Gynaecological Cancer Research, The University of Queensland, QLD, Australia; Royal Brisbane and Women's Hospital, Herston, QLD, Australia. Electronic address:
Corrigendum. Mifepristone treatment prior to insertion of a levonorgestrel releasing intrauterine system for improved bleeding control - a randomized controlled trial.
Hum Reprod
July 2019
Department of Women's and Children's Health, Division of Obstetrics and Gynecology, Karolinska Institutet and Karolinska University, Stockholm, Sweden.
Corrigendum to "Evaluation of a new, low-dose levonorgestrel intrauterine contraceptive system over 5 years of use" [Eur J Obstetr Gynecol Reprod Biol 210 (2017) 22-28].
Eur J Obstet Gynecol Reprod Biol
February 2019
Los Angeles Biomedical Research Institute, Harbor-UCLA Medical Center, CA, USA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!